Pluri Inc.

Regulatory Filings • Aug 6, 2008

8-K 1 zk85642.htm Created by EDGAR Ease Plus (EDGAR Ease+) Project: \Backup\office\EDGAR Filing\Pluristem Therapeutics Inc\85642\a85642.eep Control Number: 85642 Rev Number: 1 Client Name: Pluristem Therapeutics Inc Project Name: 8-K Firm Name: Zadok-Keinan Ltd 8-K MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation"

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation"

Form 8-K

MARKER FORMAT-SHEET="Head Major Center Bold 1-TNR" FSL="Workstation"

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 6, 2008 (August 5, 2008)

MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation"

PLURISTEM THERAPEUTICS INC. (Exact name of registrant as specified in its charter)

Nevada	001-31392	98-0351734
(State or other jurisdiction of incorporation)	(Commission file number)	(I.R.S. Employer Identification Number)

MATAM Advanced Technology Park
Building No. 20
Haifa, Israel	31905
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: 011 972 74 710 7171

n/a (Former name or former address, if changed since last report)

MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation"

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation"

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation"

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation"

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

MARKER FORMAT-SHEET="Para Hang Lv 1-TNR" FSL="Workstation"

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

MARKER FORMAT-SHEET="Exhibit Index Hang" FSL="Workstation"

Item 1.01 Entry into a Material Definitive Agreement

MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation"

On August 5, 2008, we entered into securities purchase agreements with two investors pursuant to which the investors agreed to purchase 1,391,304 shares of our common stock ("Common Stock") and warrants ("Warrants") to purchase 695,652 shares of Common Stock (the Warrants together with the Common Stock, the "Units"). The price per share of Common Stock is $1.15, and the exercise price of the Warrants is $1.90. The Warrants will be exercisable after six months for a period of five years. The closing is scheduled to take place no later than August 8, 2008.

MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation"

A copy of the form of Warrant is attached as Exhibit 4.1 to this report and is incorporated herein by reference. The description of the Warrants is a summary only and is qualified in its entirety by reference to Exhibit 4.1. A copy of the form of securities purchase agreement is attached as Exhibit 10.1 to this report and is incorporated herein by reference.

MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation"

Rodman & Renshaw, LLC acted as placement agent, on a best efforts basis, for the offering and will receive a placement fee equal to 6% of the gross purchase price of the Units (excluding any consideration that may be paid in the future upon exercise of the Warrants) as well as warrants to purchase 83,478 shares of Common Stock at an exercise price of $1.44 per share. Subject to FINRA Rule 2710, the placement agent warrants may be exercised after six months through and including August 5, 2013. A copy of the Placement Agency Agreement is attached as Exhibit 1.1 to this report and is incorporated herein by reference.

MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation"

The offering was made pursuant to our shelf registration statement on Form S-3 (File No. 333-151761). We are filing with the SEC, pursuant to Rule 424(b) under the Securities Act of 1933, as amended, a prospectus supplement and base prospectus related to the offering.

MARKER FORMAT-SHEET="Exhibit Index Hang" FSL="Workstation"

Item 9.01 Financial Statements and Exhibits

(d) Exhibits:

MARKER FORMAT-SHEET="Exhibit Index Hang" FSL="Workstation"

1.1 Placement Agency Agreement, dated July 31, 2008, by and between the registrant and Rodman & Renshaw, LLC.

MARKER FORMAT-SHEET="Exhibit Index Hang" FSL="Workstation"

4.1 Form of Common Stock Purchase Warrant dated August 5, 2008

MARKER FORMAT-SHEET="Exhibit Index Hang" FSL="Workstation"

5.1 Opinion of Zysman, Aharoni, Gayer & Co./ Sullivan & Worcester LLP

MARKER FORMAT-SHEET="Exhibit Index Hang" FSL="Workstation"

10.1 Form of Securities Purchase Agreement dated August 5, 2008

MARKER FORMAT-SHEET="Exhibit Index Hang" FSL="Workstation"

23.1 Consent of Zysman, Aharoni, Gayer & Co./ Sullivan & Worcester LLP (included in Exhibit 5.1).

SIGNATURES

MARKER FORMAT-SHEET="Para Indent Lv 0-TNR" FSL="Workstation"

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARKER FORMAT-SHEET="Signature (Single)" FSL="Workstation"

Date: August 6, 2008 PLURISTEM THERAPEUTICS INC. By: /s/ Yaky Yanay —————————————— Yaky Yanay Chief Financial Officer